We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Scintigraphic detection of bone metastases and radionuclide therapy for palliative purpose with Sr-89.
- Authors
Anton, Iuliana; Zaporoscenco, Romaniţa
- Abstract
Many patients with advanced malignancy develop evolutive bone metastases. Although bone metastases may be clinically silent, the patients suffer from intense bone pain that lowers the quality of life. Therefore, it is necessary for these metastases to be discovered as early as possible, whole-body bone scintigraphy having an important role in achieving this goal. Before bone metastases cause pain, it is very important that radionuclide therapy be started as soon as possible. Radionuclide therapy is the alternative, sometimes complementary, in an attempt to reduce intense and unbearable pain caused by bone metastases. Currently, a radionuclide such as Strontium-89 is recommended for palliative use, especially in patients with multiple wide-spread bone metastases. This radionuclide is mainly bound by phosphonates that, due to their affinity for the metabolic very active bone tissue, reach directly and target bone metastases. The main setting are osteoblastic lesions, but part of the amount of radiopharmaceutical also reaches osteolytic lesions. Radionuclide systemic therapy is effective in reducing pain, increases quality of life and reduces the need for analgesics. This effect lasts on average for several months, and the treatment can be repeated if necessary.
- Subjects
BONE metastasis; RADIOISOTOPES; PALLIATIVE treatment; DIAGNOSIS
- Publication
Oncolog-Hematolog, 2017, Issue 39, p62
- ISSN
2066-8716
- Publication type
Abstract